Gilead’s TIGIT Program Perks Up After Lung Cancer Letdown

Oncology, HIV Offer R&D Catalysts In 2024

The drug maker announced early data for zimberelimab/domvanalimab in gastrointestinal cancers that it called encouraging, though an analyst was more skeptical due to limited interpretability.

Gilead Sciences, Inc. got what it called encouraging news from its anti-PD-1/TIGIT program just before announcing its third quarter earnings as a Phase II study showed clinical activity for the immuno-oncology combination in upper gastrointestinal cancers. It also highlighted a number of oncology, inflammation and virology catalysts for 2024, including earlier-than-expected data for its long-acting HIV pre-exposure prophylaxis (PrEP) program.

Foster City, CA-based Gilead announced its third quarter earnings on 7 November, with overall revenues of $7.1bn that were flat compared with $7bn in the third quarter of 2022, but...

Key Takeaways

Gilead announced early data from a Phase II study of zimberelimab/domvanalimab in upper GI cancers the same day it announced Q3 earnings.
The...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

29 May 2025

• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

29 May 2025

• By Jung Won Shin

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.

Sun On Leqselvi US Launch Ahead, MFN Pricing And Pipeline Changes

28 May 2025

• By Anju Ghangurde

Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.

Stock Watch: Q1 Sales Trends And Forex Muddle Pharma Outlook

26 May 2025

• By Andy Smith

Pharma firms tended to downplay first-quarter trends in full-year guidance. However, raised guidance seems fragile amid ongoing foreign exchange effects and Medicare Part D redesign pressures.